SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab adjuvant therapy alone in patients with technically resectable hepatocellular carcinoma.
Epistemonikos ID: faec20e5a0143a3908465b9919b9e1e46f3c66d4
First added on: May 09, 2024